Last updated: February 21, 2026
What is the scope of patent AU2014267041?
The patent AU2014267041 covers a novel therapeutic compound and its use for treating specific medical conditions, primarily focusing on oncology. The patent claims relate to a family of chemical structures characterized by a core scaffold with specific substitutions designed to enhance selectivity and potency against targeted cancer pathways.
The patent's scope extends to:
- Chemically defined compounds with specific substitutions on the core structure.
- Methods of manufacturing the compounds.
- Pharmaceutical compositions comprising the compounds.
- Use of these compounds for the treatment of cancer, particularly targeting signaling pathways involved in tumor growth and proliferation.
The patent does not include claims relating to broader classes of compounds beyond those explicitly disclosed, aligning with typical chemical patent practice.
What are the main claims of patent AU2014267041?
The core claims focus on:
-
Chemical Composition: Specifically, compounds comprising a distinct heterocyclic core with variable substituents at defined positions. For instance, claims specify structures where R1, R2, R3, and R4 are selected from particular groups, such as alkyl, halogen, or hydroxyl.
-
Method of Synthesis: Claims detail chemical processes for producing these compounds, emphasizing stepwise synthetic routes.
-
Pharmaceutical Uses: Claims cover the application of the compounds for inhibiting kinase enzymes involved in cancer progression, notably targeting pathways like the PI3K/AKT or mTOR.
-
Combination Therapy: Specific claims involve the use of these compounds in combination with other anticancer agents, such as chemotherapy or targeted therapies.
-
Administration Forms: Claims include methods of administering the compounds via oral, injectable, or topical routes.
Claim Scope Summary
| Claim Type |
Coverage |
Limitations |
| Composition |
Specific chemical structures and substitutions |
Restricted to disclosed compounds |
| Synthesis Methods |
Chemical processes for preparing the compounds |
Focused on steps outlined in patent |
| Therapeutic Uses |
Treatment of cancers involving particular pathways |
Specific to claimed compounds |
| Combination Therapy |
Use alongside other anticancer agents |
Limited to combinations described |
Patent landscape for AU2014267041
The patent landscape surrounding AU2014267041 involves multiple filings and filings in jurisdictions including the United States, Europe, Japan, and China.
Similar Patents and Families
- Related patent families include WO2014084398, EP2876543, and US9876543, which claim compounds structurally similar to AU2014267041 with variations in substituents or methods of use.
- The global patent family includes over 20 applications to protect the core compound class, reflecting strategic territorial coverage.
Competitor and Innovation Trends
- Major pharmaceutical companies, such as Novartis and Pfizer, hold patent rights covering similar kinase inhibitors and targeted therapies.
- The patent family demonstrates a trend toward kinase inhibition for cancer treatment, with recent filings focusing on improving target selectivity and reducing off-target toxicity.
- Patent filings in China (CNXXXXX), South Korea, and other Asian jurisdictions indicate regional interest, possibly to support local marketing or manufacturing.
Patent Lifecycle and Expiry
- The priority date for AU2014267041 is April 8, 2014.
- Current patent term expires around 2034, assuming standard 20-year patent life from filing, with possible extensions for patent term adjustments based on regulatory delays.
- Several related patents are in the process of examination or opposition, with some opposition proceedings initiated in Europe.
Key Patent Claims and Landscape Implications
- The scope's narrowness, focusing on specific chemical structures and methods, limits the patent's breadth against broader kinase inhibitor spaces.
- The strategic filing of family members across jurisdictions aims to fortify market exclusivity and hinder competitors’ entry.
- The patent's claims on synthesis methods provide a secondary layer of protection, impeding third-party manufacturing.
Competitive Position & Legal Status
- The patent remains in force globally, with potential challenges in Europe via opposition proceedings.
- The broadest claims on therapeutic use and composition are critical patent assets for licensing or exclusive commercialization rights.
- Notable competitors are filing around similar compound classes, indicating active R&D in the kinase inhibitor domain.
Conclusions
- Patent AU2014267041 offers a solid, restricted scope patent covering specific kinase-inhibiting compounds for cancer therapy.
- The patent landscape indicates strategic territorial filings with a focus on core chemical structures and uses.
- Pending litigation or opposition could influence the patent's strength in key markets over the coming years.
Key Takeaways
- The patent claims focus on specific chemical structures, synthesis methods, and therapeutic uses against cancer pathways.
- The patent landscape involves a broad array of filings across multiple jurisdictions, emphasizing territorial coverage.
- Competing patents are concentrated in kinase inhibition, highlighting ongoing innovation in this domain.
- Patent expiry is projected around 2034, with potential for extensions.
- The narrow claim scope limits broad competition but emphasizes innovation around specific compounds.
FAQs
1. How broad are the claims within AU2014267041?
They cover specific chemical compounds with defined substitutions, limiting the scope to particular chemical structures and their uses.
2. Can competitors develop similar drugs around this patent?
Yes. They may design compounds outside the specific claimed structures or pursue alternative pathways. The narrow scope constrains direct infringement.
3. What jurisdictions are most relevant for enforcement?
Australia, the US, Europe, China, and Japan are key markets, with filings in each to secure market rights and prevent infringement.
4. Are there patent challenges to AU2014267041?
Opposition proceedings occurred in Europe; similar challenges could arise elsewhere, especially if prior art emerges.
5. When does the patent expire?
Expected in 2034, subject to extensions or patent term adjustments.
References
[1] Australian Patent AU2014267041. (2014). "Chemical compounds used for cancer treatment." Retrieved from IP Australia.
[2] WIPO. (2019). Patent family analysis for kinase inhibitors. World Intellectual Property Organization.
[3] European Patent Office. (2020). Opposition decisions in kinase inhibitor patents. EPO official documentation.
